Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C5H6NO3.Na |
| Molecular Weight | 151.0958 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[O-]C(=O)C1CCC(=O)N1
InChI
InChIKey=CRPCXAMJWCDHFM-UHFFFAOYSA-M
InChI=1S/C5H7NO3.Na/c7-4-2-1-3(6-4)5(8)9;/h3H,1-2H2,(H,6,7)(H,8,9);/q;+1/p-1
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C5H6NO3 |
| Molecular Weight | 128.106 |
| Charge | -1 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.medicines.org.uk/emc/medicine/18948
http://www.centerchem.com/Products/DownloadFile.aspx?FileID=6642
Curator's Comment: description was created based on several sources, including
https://www.medicines.org.uk/emc/medicine/18948
http://www.centerchem.com/Products/DownloadFile.aspx?FileID=6642
Pyroglutamic acid (also known as PCA, 5-oxoproline, pidolic acid, or pyroglutamate for its basic form) exists as two distinct enantiomers: (2R) or D and (2S) or L. L-form is a metabolite in the glutathione cycle that is converted to glutamate by 5-oxoprolinase. L-Pyroglutamic acid is produced in the skin through the arginine-citrulline-ornitine-glutamic pathway. The free acid is not hygroscopic; however, the sodium salts of this acid are more hygroscopic than glycerine. Therefore, formulation of this acid is suggested as a defense against dehydration, for skin conditions involving desquamation. Hydromol Cream (main component of that is sodium pyrrolidone carboxylate (L form)) is a soft cream which moisturises the skin. Hydromol Cream contains a naturally occurring moisturising agent as well as oils, which prevent moisture loss from the skin. This helps to relieve itch, lubricate and soften the skin. Hydromol Cream is used to treat any condition in which dry skin is a feature such as eczema, ichthyosis (hereditary dry skin) and senile pruritus (itching that may occur in old age). L-Pyroglutamic acid is present in living cells has been reported from archaebacteria to humans, and its occurrence in living cells has been known for over a century. Despite its almost ubiquitous presence, the role of pyroglutamic acid in living cells is poorly understood. Pyroglutamic acid is found as an N-terminal modification in many neuronal peptides and hormones that also include the accumulating peptides in Alzheimer’s disease and familial dementia. The modification is also observed in proteins that include many antibodies, some enzymes and structural proteins.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7080082
Curator's Comment: Known to be CNS penetrant in rats. Human data not available
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Hydromol® CREAM Approved UseDry skin conditions including dermatitis, eczema, ichthyosis and senile pruritus. |
|||
| Palliative | Hydromol® CREAM Approved UseDry skin conditions including dermatitis, eczema, ichthyosis and senile pruritus. |
|||
| Palliative | Hydromol® CREAM Approved UseDry skin conditions including dermatitis, eczema, ichthyosis and senile pruritus. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| A second gene encodes the anti-diuretic hormone in the insect, Rhodnius prolixus. | 2010-04-12 |
|
| Structure-activity relationships for in vitro diuretic activity of CAP2b in the housefly. | 2007-01 |
|
| Sequence and expression of the CAPA/CAP2b gene in the tobacco hawkmoth, Manduca sexta. | 2004-10 |
|
| Bone marrow stem cell protection from chemotherapy by low--molecular-weight compounds. | 2001-02 |
|
| Effect of the hemoregulatory peptide (pEEDCK)2 (pyroGlu-Glu-Asp-Cys-Lys)2 and MIP-1alpha is reduced in bone marrow cultures from patients with chronic myeloid leukemia (CML). | 2001 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:10:01 GMT 2025
by
admin
on
Mon Mar 31 18:10:01 GMT 2025
|
| Record UNII |
469OTG57A2
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID20885432
Created by
admin on Mon Mar 31 18:10:01 GMT 2025 , Edited by admin on Mon Mar 31 18:10:01 GMT 2025
|
PRIMARY | |||
|
C45678
Created by
admin on Mon Mar 31 18:10:01 GMT 2025 , Edited by admin on Mon Mar 31 18:10:01 GMT 2025
|
CONCEPT | Industrial Aid | ||
|
23666346
Created by
admin on Mon Mar 31 18:10:01 GMT 2025 , Edited by admin on Mon Mar 31 18:10:01 GMT 2025
|
PRIMARY | |||
|
469OTG57A2
Created by
admin on Mon Mar 31 18:10:01 GMT 2025 , Edited by admin on Mon Mar 31 18:10:01 GMT 2025
|
PRIMARY | |||
|
469OTG57A2
Created by
admin on Mon Mar 31 18:10:01 GMT 2025 , Edited by admin on Mon Mar 31 18:10:01 GMT 2025
|
PRIMARY | |||
|
C84168
Created by
admin on Mon Mar 31 18:10:01 GMT 2025 , Edited by admin on Mon Mar 31 18:10:01 GMT 2025
|
PRIMARY | |||
|
1364924
Created by
admin on Mon Mar 31 18:10:01 GMT 2025 , Edited by admin on Mon Mar 31 18:10:01 GMT 2025
|
PRIMARY | RxNorm | ||
|
54571-67-4
Created by
admin on Mon Mar 31 18:10:01 GMT 2025 , Edited by admin on Mon Mar 31 18:10:01 GMT 2025
|
PRIMARY | |||
|
259-234-9
Created by
admin on Mon Mar 31 18:10:01 GMT 2025 , Edited by admin on Mon Mar 31 18:10:01 GMT 2025
|
PRIMARY | |||
|
SUB28928
Created by
admin on Mon Mar 31 18:10:01 GMT 2025 , Edited by admin on Mon Mar 31 18:10:01 GMT 2025
|
PRIMARY | |||
|
100000092937
Created by
admin on Mon Mar 31 18:10:01 GMT 2025 , Edited by admin on Mon Mar 31 18:10:01 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |